Biohaven’s Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
_ “Biohaven Ltd. has fully enrolled its Phase 2 proof-of-concept trial evaluating taldefgrobep alfa as a monotherapy for overweight and obesity, marking a key milestone in developing a novel treatment that targets the myostatin-activin pathway to promote high-quality weight loss by reducing fat mass while preserving or increasing lean muscle mass. The randomized, double-blind, placebo-controlled … Read more
